U.S. Drug Enforcement Administration

The U.S. Drug Enforcement Administration is presented as a federal drug-enforcement agency confronting the opioid crisis through surveillance, diversion control, and an unusual effort to enlist a manufacturer in policing its own product. Its record in the account is mixed: an official initially treated the spread of illicit opioids beyond southwest Virginia as unlikely, while the agency later developed a national plan focused on Purdue Pharma and OxyContin. The account also shows how that enforcement role could be complicated by political negotiation and by the separate responsibilities of regulators and prosecutors.

Reading the Spread of the Crisis

By 2001, the Roanoke-based medical examiner had counted one OxyContin death in southwest Virginia in 1997, three the next year, and sixteen in 1999. Those figures were not publicly exposed until 2001. In that period, a U.S. Drug Enforcement Administration official told a Richmond reporter that illicit opioids were unlikely to spread beyond the mountains to the state capital, describing southwest Virginia as distinctive. The official also acknowledged other OxyContin-abuse hot spots, including rural Maine, Cincinnati, Baltimore, and Charleston, West Virginia. The contrast between the agency’s cautious assessment of further spread and its recognition of other affected places captures an early uncertainty in how the crisis was being understood.

The book places that uncertainty against an expanding pattern of prescription-drug misuse and diversion. The agency’s later focus on OxyContin did not begin from an assumption that the problem was confined to one community; its national action plan instead treated the drug’s distribution and marketing as matters requiring broader scrutiny.

The National Action Plan

After Art Van Zee and the Lee Coalition for Health organized a petition drive seeking an OxyContin recall, the U.S. Drug Enforcement Administration developed a national action plan the following month. It asked Purdue Pharma to limit the drug’s distribution, reconsider its marketing strategy, and consider reformulating it to resist abuse. The plan was a first in the agency’s history: it targeted a particular drug and sought to have its manufacturer help police diversion and misuse.

Purdue responded with a ten-point plan. The measures included tamper-resistant prescription pads, an educational program warning teenagers about prescription-drug dangers, and a $100,000 grant toward a statewide prescription monitoring program intended to curb doctor-shopping. The company also stopped distributing its 160-milligram OxyContin tablet and reduced shipments to Mexico after reports that pills were being smuggled back into the United States. These company actions followed the agency’s requests, but they did not resolve the wider conflict over whether corporate controls and education could adequately address a drug already being misused.

The FDA’s July 2001 black-box warning was a separate regulatory action, announced after the agency worked with Purdue. It was the strongest type of prescription-drug warning and was intended to help prevent inappropriate prescribing, misuse, and diversion. Purdue’s spokesman played down the warning, characterizing it as largely graphic design and emphasizing the company’s distinction between legitimate patients and people who crushed, snorted, or injected the drug. The episode shows that the DEA’s distribution-focused plan existed alongside FDA oversight, but the two agencies’ roles and actions should not be conflated.

Diversion Control and Corporate Negotiation

The U.S. Drug Enforcement Administration was also investigating lax security standards at Purdue’s manufacturing plants after the 2001 arrest of two employees accused of attempting to steal thousands of pills. In a related matter, Rudy Giuliani brokered a behind-the-scenes negotiation over the fine for the Purdue affiliate that operated the New Jersey pill factory. The company agreed to a $2 million civil penalty without admitting wrongdoing; the agency’s diversion control manager had argued for a $10 million fine and was left angry by the outcome.

The manager’s responsibility was to ensure that drugs were used lawfully and not diverted into illicit trafficking. She believed Giuliani and Purdue executives had gone over her head to her superior in an effort to gain political access and insight. At a luncheon, Giuliani had also helped raise $20,000 for a new historical exhibit at the DEA Museum. The account establishes these events and the official’s suspicion, but does not present the fundraiser as proof of a causal link to the negotiated penalty. Together, they reveal the pressures and institutional sensitivities surrounding diversion enforcement when a powerful company faced scrutiny.

The Limits of the Agency’s Role

The later criminal case against Purdue involved a different part of the federal enforcement system. In 2006, federal prosecutors considered a broader set of felony charges, but the case was narrowed as it moved through the U.S. Department of Justice; Purdue’s lawyers and Giuliani also lobbied against indicting the company’s executives on felony counts. On the eve of the plea agreement’s expiration, a senior Justice Department official called John Brownlee at home, at the request of a Purdue lawyer, and urged him to extend the deadline. Brownlee refused the pressure, and Purdue accepted the agreement that night.

Those negotiations were prosecutorial actions, not actions attributed to the U.S. Drug Enforcement Administration. Their relevance is institutional: the account distinguishes the agency’s work on monitoring and diversion from the Justice Department’s decisions about charges and plea terms. The DEA’s interventions were significant—the national plan was unprecedented, and its diversion-control officials pressed for stronger consequences—but the broader response to OxyContin depended on multiple federal bodies whose decisions did not always align.